Optimized production and concentration of lentiviral vectors containing large inserts

Generation of high titer lentiviral stocks and efficient virus concentration are central to maximize the utility of lentiviral technology. Here we evaluate published protocols for lentivirus production on a range of transfer vectors differing in size (7.5–13.2 kb). We present a modified virus production protocol robustly yielding useful titers (up to 107/ml) for a range of different transfer vectors containing packaging inserts up to 7.5 kb. Moreover, we find that virus recovery after concentration by ultracentrifugation depends on the size of the packaged inserts, heavily decreasing for large packaged inserts. We describe a fast (4 h) centrifugation protocol at reduced speed allowing high virus recovery even for large and fragile lentivirus vectors. The protocols outlined in the current report should be useful for many labs interested in producing and concentrating high titer lentiviral stocks. Copyright © 2007 John Wiley & Sons, Ltd.

[1]  A. Consiglio,et al.  A new-generation stable inducible packaging cell line for lentiviral vectors. , 2001, Human gene therapy.

[2]  J. Reiser.  Production and concentration of pseudotyped HIV-1-based gene transfer vectors , 2000, Gene Therapy.

[3]  M. Fussenegger,et al.  Detailed design and comparative analysis of protocols for optimized production of high-performance HIV-1-derived lentiviral particles. , 2005, Metabolic engineering.

[4]  T. Crombleholme,et al.  Optimized large-scale production of high titer lentivirus vector pseudotypes. , 2004, Journal of virological methods.

[5]  Y. Ron,et al.  An inducible packaging cell system for safe, efficient lentiviral vector production in the absence of HIV-1 accessory proteins. , 2001, Virology.

[6]  H. Bujard,et al.  Doxycycline-regulated lentiviral vector system with a novel reverse transactivator rtTA2S-M2 shows a tight control of gene expression in vitro and in vivo , 2003, Gene Therapy.

[7]  L. Kedes,et al.  A high-titer lentiviral production system mediates efficient transduction of differentiated cells including beating cardiac myocytes. , 1999, Journal of molecular and cellular cardiology.

[8]  B. Karolewski,et al.  Comparison of transfection conditions for a lentivirus vector produced in large volumes. , 2003, Human gene therapy.

[9]  D. Israeli,et al.  Transactivator and structurally optimized inducible lentiviral vectors. , 2004, Molecular Therapy.

[10]  C. Lois,et al.  Retroviruses as tools to study the immune system. , 2001, Current opinion in immunology.

[11]  T. Kafri,et al.  A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  L. Crofford,et al.  Highly efficient genetic transduction of primary human synoviocytes with concentrated retroviral supernatant , 2002, Arthritis Research & Therapy.

[13]  I. Verma,et al.  Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  Michael T. McManus,et al.  A lentivirus-based system to functionally silence genes in primary mammalian cells, stem cells and transgenic mice by RNA interference , 2003, Nature Genetics.

[15]  D. Trono,et al.  A Third-Generation Lentivirus Vector with a Conditional Packaging System , 1998, Journal of Virology.

[16]  D. Trono,et al.  Lentiviral vectors and antiretroviral intrinsic immunity. , 2005, Human gene therapy.

[17]  Brian Davis,et al.  Generation of a packaging cell line for prolonged large‐scale production of high‐titer HIV‐1‐based lentiviral vector , 2005, The journal of gene medicine.

[18]  M. Kumar,et al.  Systematic determination of the packaging limit of lentiviral vectors. , 2001, Human gene therapy.

[19]  R. Fässler.  Lentiviral transgene vectors , 2004, EMBO reports.

[20]  G. Cleghorn,et al.  A highly efficient and consistent method for harvesting large volumes of high-titre lentiviral vectors , 2001, Gene Therapy.

[21]  A. Logan,et al.  Factors influencing the titer and infectivity of lentiviral vectors. , 2004, Human gene therapy.

[22]  D. Nesbeth,et al.  Metabolic biotinylation of lentiviral pseudotypes for scalable paramagnetic microparticle-dependent manipulation. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[23]  D. Trono,et al.  A stable system for the high-titer production of multiply attenuated lentiviral vectors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.

[24]  M. Wiznerowicz,et al.  A versatile tool for conditional gene expression and knockdown , 2006, Nature Methods.

[25]  A. Blesch.  Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer. , 2004, Methods.

[26]  L. Naldini,et al.  Gene therapy of storage disorders by retroviral and lentiviral vectors. , 2005, Human Gene Therapy.